Schizophrenia. Schizophrenia
Conditions
Interventions
Intervention 1: Intervention group: Cilostazol tablets are orally administered at a dose of 25 mg twice daily for 2 weeks and then 50 mg twice daily for 6 weeks. Intervention 2: Control group: placebo
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: Diagnosis of schizophrenia based on DSM-5 criteria aged 18-64 years completed consent form by the patient or his family at least the eighth grade education
Exclusion criteria
Exclusion criteria: Simultaneous psychiatric disorders liver disorders medical illness Use of opioid substances other than cigarettes A hypersensitivity reaction or any untoward side effects caused by the drug Use of other interfering drugs Serious cognitive impairment blood or Platelet problem Contradictory with taking medication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Score in PANSS questionnaire. Timepoint: Before starting the study and at times, 0, 2, 4 and 8 weeks after starting treatment. Method of measurement: Schizophrenia symptoms assessment questionnaire PANSS.;Memory score in digit span. Timepoint: Before starting the study and at times, 0, 2, 4 and 8 weeks after starting treatment. Method of measurement: Digit span questionnaire.;Cognition scoring based on Wisconsin card sorting test. Timepoint: Before starting the study and at times, 0, 2, 4 and 8 weeks after starting treatment. Method of measurement: Wisconsin card sorting test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammadreza Fayyazi Bordbar
Mashhad University of Medical Sciences
Outcome results
None listed